Emmaus Life Sciences Inc Revenue Growth Rates (EMMAW), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Emmaus Life Sciences Inc   (EMMAW)
 

EMMAW's Revenue Growth by Quarter and Year

Emmaus Life Sciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EMMAW Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 3.85
3rd Quarter September 2.82
2nd Quarter June 2.41
1st Quarter March 3.09
FY 12.17

EMMAWs Annual Revenue
Emmaus Life Sciences Inc 's Revenue in the fiscal year 2025 $ 12.45 millions
Emmaus Life Sciences Inc 's Revenue in the fiscal year 2024 $ 16.45 millions
Emmaus Life Sciences Inc 's Revenue in the fiscal year 2023 $ 29.26 millions
Emmaus Life Sciences Inc 's Revenue in the fiscal year 2022 $ 18.39 millions
Emmaus Life Sciences Inc 's Revenue in the fiscal year 2021 $ 20.61 millions




EMMAW Revenue fourth quarter 2025 Y/Y Growth Comment
Emmaus Life Sciences Inc reported fall in Revenue in the fourth quarter 2025 by -29.71% to $ 3.85 millions, from the same quarter in 2024.
The drop in the fourth quarter 2025 Emmaus Life Sciences Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 253.17%.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 96 other companies have achieved higher Revenue growth. While Emmaus Life Sciences Inc ' s Revenue drop of -29.71% ranks overall at the positon no. 1955 in the fourth quarter 2025.


EMMAW Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December -29.71 % 9.16 % 1.62 % -14.38 %
3rd Quarter September -47.58 % -50 % 150.82 % -33.9 %
2nd Quarter June -3.98 % -62.81 % 108.98 % -39.51 %
1st Quarter March -54.09 % 13.49 % 96.36 % -51.68 %
FY   -39.44 % -29.37 % 83.85 % -

Financial Statements
Emmaus Life Sciences Inc 's fourth quarter 2025 Revenue $ 3.85 millions EMMAW's Income Statement
Emmaus Life Sciences Inc 's fourth quarter 2024 Revenue $ 5.48 millions Quarterly EMMAW's Income Statement


EMMAW Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December 36.6 % 1.86 % -53.35 % 15.15 %
3rd Quarter September 17.01 % 114.34 % 59.41 % 32.82 %
2nd Quarter June -22.01 % -62.7 % 13.83 % 6.95 %
1st Quarter March -43.61 % 34.06 % 20.04 % -47.66 %
FY (Year on Year)   -39.44 % -29.37 % 83.85 % -


Back to EMMAW Growth rate Comparisons >> Back to EMMAW Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #97
Healthcare Sector #300
Overall #1955

Revenue Y/Y Growth Statistics
High Average Low
1827.56 % 253.17 % -54.05 %
(Jun 30 2020)   (Sep 30 2022)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #97
Healthcare Sector #300
Overall #1955
Revenue Y/Y Growth Statistics
High Average Low
1827.56 % 253.17 % -54.05 %
(Jun 30 2020)   (Sep 30 2022)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Emmaus Life Sciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1054.46 % 58.07 % -66.85 %
(Sep 30 2019)  


EMMAW's IV. Quarter Q/Q Revenue Comment
Emmaus Life Sciences Inc achieved in the IV. Quarter 2025 below company average Revenue jump of 36.6% quarter on quarter, to $ 3.85 millions.

IV. Quarter 2025 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 1.86% in the IV. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 194 other companies have achieved higher Revenue quarter on quarter growth. While Emmaus Life Sciences Inc 's Revenue growth quarter on quarter, overall rank is 3671.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #195
Healthcare Sector #541
Overall #3671
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #195
Healthcare Sector #541
Overall #3671
Revenue Q/Q Growth Statistics
High Average Low
1054.46 % 58.07 % -66.85 %
(Sep 30 2019)  


EMMAW's IV. Quarter Q/Q Revenue Comment
Emmaus Life Sciences Inc achieved in the IV. Quarter 2025 below company average Revenue jump of 36.6% quarter on quarter, to $ 3.85 millions.

IV. Quarter 2025 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 1.86% in the IV. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 194 other companies have achieved higher Revenue quarter on quarter growth. While Emmaus Life Sciences Inc 's Revenue growth quarter on quarter, overall rank is 3671.


Emmaus Life Sciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)
Cumulative Revenue 12 Months Ending $ 12.17 $ 13.79 $ 16.35 $ 16.45 $ 20.09
Y / Y Revenue Growth (TTM) -39.43 % -29.73 % -34.61 % -43.76 % -29.42 %
Year on Year Revenue Growth Overall Ranking # 3011 # 3143 # 771 # 187 # 118
Seqeuential Revenue Change (TTM) -11.79 % -15.66 % -0.61 % -18.09 % 2.34 %
Seq. Revenue Growth (TTM) Overall Ranking # 2672 # 3038 # 2864 # 1816 # 1721


Cumulative Revenue growth Comment
Emmaus Life Sciences Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -39.43% year on year, at Dec 31 2025 compare to the -29.73% decrease at Jun 30 2025. If the Emmaus Life Sciences Inc 's fiscal year would end at Dec 31 2025, annual Revenue would be $12 millions.

In the Healthcare sector 406 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3011, from total ranking in previous quarter at 3143.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 126
Healthcare Sector # 407
Overall # 3011

Revenue TTM Y/Y Growth Statistics
High Average Low
1827.56 %
 253.17 %
-54.05 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 126
Sector # 380
S&P 500 # 2672
Cumulative Revenue growth Comment
Emmaus Life Sciences Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -39.43% year on year, at Dec 31 2025 compare to the -29.73% decrease at Jun 30 2025. If the Emmaus Life Sciences Inc 's fiscal year would end at Dec 31 2025, annual Revenue would be $12 millions.

In the Healthcare sector 406 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3011, from total ranking in previous quarter at 3143.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 126
Healthcare Sector # 407
Overall # 3011

Revenue TTM Y/Y Growth Statistics
High Average Low
1827.56 %
253.17 %
-54.05 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 126
Sector # 380
S&P 500 # 2672




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
EMMAW's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Ardent Health Inc -0.08%$ -0.075 millions
Chemed Corporation-0.10%$ -0.103 millions
Embecta Corp -0.15%$ -0.153 millions
Bruker Corporation-0.24%$ -0.245 millions
Vaso Corporation-0.38%$ -0.376 millions
Bio techne Corp-0.54%$ -0.542 millions
Lftd Partners Inc -0.76%$ -0.763 millions
Xtant Medical Holdings Inc -0.82%$ -0.821 millions
Charles River Laboratories International inc -0.83%$ -0.830 millions
Koninklijke Philips Nv-1.04%$ -1.038 millions
Evotec Se-1.08%$ -1.078 millions
Pfizer Inc-1.16%$ -1.160 millions
Adapthealth Corp -1.21%$ -1.209 millions
Avantor Inc -1.36%$ -1.364 millions
Alpha Teknova Inc -1.42%$ -1.422 millions
Skinhealth Systems Inc -1.57%$ -1.569 millions
Pediatrix Medical Group Inc -1.71%$ -1.711 millions
Integra Lifesciences Holdings Corp-1.74%$ -1.744 millions
Edap Tms Sa-1.78%$ -1.783 millions
Vivos Therapeutics Inc -2.18%$ -2.178 millions
Absci Corp-2.26%$ -2.256 millions
Prestige Consumer Healthcare Inc -2.30%$ -2.303 millions
Perrigo Company Plc-2.52%$ -2.521 millions
Bionano Genomics Inc -2.60%$ -2.597 millions
Haemonetics Corporation-2.64%$ -2.636 millions
Amphastar Pharmaceuticals Inc -2.79%$ -2.790 millions
Strata Skin Sciences Inc-2.97%$ -2.966 millions
Plus Therapeutics Inc -3.19%$ -3.187 millions
Harvard Bioscience Inc -3.23%$ -3.226 millions
Brookdale Senior Living Inc -3.44%$ -3.439 millions


About Emmaus Life Sciences Inc Revenue Growth Rates (EMMAW), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Emmaus Life Sciences Inc (CIK 822370).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-351833
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Emmaus Life Sciences Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.